nach oben

European Archives of Psychiatry and Clinical Neuroscience

Erschienen in:

29.03.2019 | Short Communication

Lack of dopamine D₁ receptors in the antidepressant actions of (R)-ketamine in a chronic social defeat stress model

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

It is reported that dopamine D₁ receptors in the medial prefrontal cortex play a role in the antidepressant actions of (R,S)-ketamine. However, its role in the antidepressant actions of (R)-ketamine, which is more potent than (S)-ketamine, is unknown. In the locomotion test, tail suspension test, forced swimming test and 1% sucrose preference test, pretreatment with dopamine D₁ receptor antagonist SCH-23390 did not block the antidepressant effects of (R)-ketamine in the susceptible mice after chronic social defeat stress. These findings suggest that dopamine D₁ receptors may not play a major role in the antidepressant actions of (R)-ketamine.

Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB (2015) Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 172(10):950–966CrossRef

Kishimoto T, Chawla JM, Hagi K, Zarate CA, Kane JM, Bauer M, Correll CU (2016) Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med 46(7):1459–1472CrossRef

Zhang K, Hashimoto K (2019) An update on ketamine and its two enantiomers as rapid-acting antidepressants. Expert Rev Neurother 19(1):83–92CrossRef

Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg FM (1997) Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol 333(1):99–104CrossRef

Fukumoto K, Toki H, Iijima M, Hashihayata T, J-i Yamaguchi, Hashimoto K, Chaki S (2017) Antidepressant potential of (R)-ketamine in rodent models: comparison with (S)-ketamine. J Pharmacol Exp Ther 36(1):9–16CrossRef

Zhang JC, Li SX, Hashimoto K (2014) R(−)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine. Pharmacol Biochem Behav 116:137–141CrossRef

Yang C, Shirayama Y, Jc Zhang, Ren Q, Yao W, Ma M, Dong C, Hashimoto K (2015) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5:e632CrossRef

Yang C, Qu Y, Abe M, Nozawa D, Chaki S, Hashimoto K (2017) (R)-ketamine shows greater potency and longer lasting antidepressant effects than its metabolite (2R,6R)-hydroxynorketamine. Biol Psychiatry 82(5):e43–e44CrossRef

Yang C, Qu Y, Fujita Y, Ren Q, Ma M, Dong C, Hashimoto K (2017) Possible role of the gut microbiota-brain axis in the antidepressant effects of (R)-ketamine in a social defeat stress model. Transl Psychiatry 7(12):1294CrossRef

10.

Yang C, Ren Q, Qu Y, Zhang J-C, Ma M, Dong C, Hashimoto K (2018) Mechanistic target of rapamycin–independent antidepressant effects of (R)-ketamine in a social defeat stress model. Biol Psychiatry 83(1):18–28CrossRef

11.

Zhang K, Ma M, Dong C, Hashimoto K (2018) Role of inflammatory bone markers in the antidepressant actions of (R)-ketamine in a chronic social defeat stress model. Int J Neuropsychopharmacol 21(11):1025–1030PubMedPubMedCentral

12.

Hashimoto K (2016) Letter to the Editor: R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity. Psychol Med 46(11):2449–2451CrossRef

13.

Yang C, Han M, J-c Zhang, Ren Q, Hashimoto K (2016) Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine. Psychiatry Res 239:281–283CrossRef

14.

Hashimoto K, Kakiuchi T, Ohba H, Nishiyama S, Tsukada H (2017) Reduction of dopamine D_2/3 receptor binding in the striatum after a single administration of esketamine, but not R-ketamine: a PET study in conscious monkeys. Eur Arch Psychiatry Clin Neurosci 267(2):173–176CrossRef

15.

Tian Z, Dong C, Fujita A, Fujita Y, Hashimoto K (2018) Expression of heat shock protein HSP-70 in the retrosplenial cortex of rat brain after administration of (R, S)-ketamine and (S)-ketamine, but not (R)-ketamine. Pharmacol Biochem Behav 172:17–21CrossRef

16.

Fuchikami M, Thomas A, Liu R, Wohleb ES, Land BB, DiLeone RJ, Aghajanian GK, Duman RS (2015) Optogenetic stimulation of infralimbic PFC reproduces ketamine’s rapid and sustained antidepressant actions. Proc Nat Acad Sci USA 112(26):8106–8111CrossRef

17.

Shirayama Y, Hashimoto K (2017) Effects of a single bilateral infusion of R-ketamine in the rat brain regions of a learned helplessness model of depression. Eur Arch Psychiatry Clin Neurosci 267(2):177–182CrossRef

18.

Hare BD, Shinohara R, Liu RJ, Pothula S, DiLeone RJ, Duman RS (2019) Optogenetic stimulation of medial prefrontal cortex Drd1 neurons produces rapid and long-lasting antidepressant effects. Nat Commun 10(1):223CrossRef

19.

Li Y, Zhu ZR, Ou BC, Wang YQ, Tan ZB, Deng CM, Gao YY, Tang M, So JH, Mu YL, Zhang LQ (2015) Dopamine D₂/D₃ but not dopamine D₁ receptors are involved in the rapid antidepressant-like effects of ketamine in the forced swim test. Behav Brain Res 279:100–105CrossRef

20.

Hashimoto K, Shirayama Y (2018) What are the causes for discrepancies of antidepressant actions of (2R,6R)-hydroxynorketamine? Biol Psychiatry 84(1):e7–e8CrossRef

21.

Chang L, Toki H, Qu Y, Fujita Y, Mizuno-Yasuhira A, Yamaguchi JI, Chaki S, Hashimoto K (2018) No sex-specific differences in the acute antidepressant actions of (R)-ketamine in an inflammation model. Int J Neuropsychopharmacol 21(10):932–937CrossRef

22.

Nugent AC, Ballard ED, Gould TD, Park LT, Moaddel R, Brutsche NE, Zarate CA Jr (2018) Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. Mol Psychiatry. https://doi.org/10.1038/s41380-018-0028-2 CrossRefPubMedPubMedCentral

23.

Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17(8):2921–2927CrossRef

24.

Ago Y, Tanabe W, Higuchi M, Tsukada S, Hashimoto K, Hashimoto H (2018) (R)-ketmaine, (S)-ketamine and their metabolites affect differentially in vivo monoamine release in the prefrontal cortex of mice: different involvement of AMPA receptor. Poster W-131 at 57th annual meeting of The American College of Neuropsychopharmacology, Hollywood, FL, 12 Dec 2018

Titel: Lack of dopamine D1 receptors in the antidepressant actions of (R)-ketamine in a chronic social defeat stress model
Publikationsdatum: 29.03.2019
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 2/2020
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI: https://doi.org/10.1007/s00406-019-01012-1

Neu im Fachgebiet Psychiatrie

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

23.04.2024 Depression antepartal oder postpartal Nachrichten

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

22.04.2024 DGIM 2024 Kongressbericht

Die Kombination aus Medikamenten und Psychotherapie gilt als effektivster Ansatz bei Depressionen. Das ist bei betagten Menschen nicht anders, trotz Besonderheiten.

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

22.04.2024 DGIM 2024 Nachrichten

Um Menschen nach der Flucht aus einem Krisengebiet bestmöglich medizinisch betreuen zu können, ist es gut zu wissen, welche Erkrankungen im jeweiligen Herkunftsland häufig sind. Dabei hilft eine Internetseite der CDC (Centers for Disease Control and Prevention).

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Default mode network connectivity change corresponds to ketamine’s delayed glutamatergic effects

Brain-derived neurotrophic factor-TrkB signaling and the mechanism of antidepressant activity by ketamine in mood disorders

Suicide in men: an underappreciated public health challenge

More assortative mating in US compared to European parents and spouses of patients with bipolar disorder: implications for psychiatric illness in the offspring

Brain-derived neurotrophic factor-TrkB signaling in the medial prefrontal cortex plays a role in the anhedonia-like phenotype after spared nerve injury